Stocks · Theme
Precision biotech & therapeutics stocks · 69 research notes
69 Precision biotech & therapeutics stocks with a dated research note: thesis, kill line and next catalyst.
Earlier themeNot among the research's active themes (last active 23 October 2026). Each stock's note below is dated on its own.
All 69 have a dated research note with a published kill line: the note's own test, stated in advance, of what would prove it wrong: a price level, a business fact, or both.
All stocksCYRXCryoPortMedium Cryoport's cold-chain business for cell and gene therapies is growing faster and posted a second positive adjusted EBITDA quarter, with 2026 revenue guidance raised to $197–199 million. The fourth-quarter report settles whether that pace…MRKMerckMedium Merck's newer drugs and under-the-skin Keytruda are carrying its growth after raised 2026 guidance on 29 October 2026; the early-February 2027 outlook shows whether moderate growth absorbs over $2 billion of generic losses.OABIOmniAbMedium OmniAb is modestly more likely to beat the S&P 500 over three months because its raised 2026 guidance and $8.3 million of nine-month operating cash inflow show partners can fund its antibody-discovery model. The fourth-quarter report,…SDGRSchrodingerMedium Schrödinger's software revenue returned to growth and its full-year contract-value guidance rose to $222–232 million, giving the shares a modest edge over the S&P 500. The fourth-quarter report, expected around late February 2027, settles…ZVRAZevra TherapeuticsMedium Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026 and the company is profitable; the EMA re-examination of arimoclomol, guided to the fourth quarter,…ABCLAbCellera BiologicsLow AbCellera's shares look more likely to lag the S&P 500 over three months, because the case rests on unproven repeat dosing of ABCL635, its monthly hot-flash injectable. The open-label extension data, guided for late 2026 to early 2027,…IBRXImmunityBioLow ImmunityBio's third-quarter Anktiva revenue of $48.7 million fell below the second quarter's $50.7 million, and the shares are more likely to lag the S&P 500 until detailed QUILT-2.005 efficacy data and a fourth-quarter revenue rebound…KODKodiak SciencesLow Kodiak Sciences' shares look more likely to lag the S&P 500 after a 161.8% three-month run that prices in the DAYBREAK win while share sales have begun. The PEAK topline, guided for December 2026, settles it.MRNAModernaLow Moderna's shares are more likely to lag the S&P 500 over three months: a 246.5% three-month gain already prices its surprise profit and melanoma vaccine, and 2027 guidance waits for the fourth-quarter report. The 18 November 2026 Jefferies…VKTXViking TherapeuticsLow Viking Therapeutics is more likely to lag the S&P 500 over three months: $960 million in cash funds its obesity Phase 3 trials, but no pivotal efficacy result is scheduled before 2027. The ObesityWeek posters from 15 November 2026 add…ABVXAbivax SAMedium Abivax's shares are modestly more likely to beat the S&P 500 over three months because the company guides its US obefazimod ulcerative colitis marketing application to the fourth quarter of 2026; a filing by 31 December 2026 settles it.BHVNBiohavenMedium Biohaven Ltd. is modestly more likely than not to beat the S&P 500 over three months: the SK Biopharmaceuticals licence has cleared US antitrust, and receipt of its $350 million payment plus the second-half 2026 RISE3 epilepsy readout…BMYBristol-Myers SquibbMedium Bristol Myers Squibb raised 2026 revenue guidance to $49.75–$50.25 billion on 29 October 2026 but cut adjusted EPS guidance to $6.35–$6.55 on licensing charges; the early-2027 report shows whether earnings power follows revenue.CLYMClimb BioMedium Climb Bio's budoprutug showed a clear antibody effect in membranous nephropathy and the third-quarter report kept funding into the second half of 2028; the December 2026 ASH immune thrombocytopenia data test whether the drug works beyond…CMPSCOMPASS PathwaysMedium Compass Pathways is modestly more likely to beat the S&P 500 over three months: its COMP360 psilocybin filing was completed on 9 November 2026 under a one-to-two-month voucher review target, and FDA acceptance and an action date decide…EWTXEdgewise TherapeuticsMedium Edgewise Therapeutics is modestly more likely than not to beat the S&P 500 over three months: FDA-cleared Phase 3 plans for heart drug EDG-7500, $1.74 billion of cash and unconfirmed takeover reports support it. The STRATUS-HCM trial…MBXMBX BiosciencesMedium MBX Biosciences is modestly more likely than not to beat the S&P 500 over three months: $481.6 million of cash funds canvuparatide into 2029, and the 12-week MBX-4291 obesity data guided for the fourth quarter of 2026 settle the second…MIRMMirum PharmaceuticalsMedium Mirum Pharmaceuticals is modestly more likely than not to lead the S&P 500 over three months: both Phase 3 hepatitis delta studies are positive and LIVMARLI sales are growing. The report expected around 25 February 2027 tests the $715–720…ONCBeOne MedicinesMedium BeOne Medicines' BRUKINSA growth and widening margins make the shares modestly more likely to beat the S&P 500 over three months; full MANGROVE lymphoma results on 13 December 2026 test the next label, and the fourth-quarter report settles…PTGXProtagonist TherapeuticsMedium Protagonist Therapeutics is modestly more likely than not to beat the S&P 500 over three months: it holds $834.6 million of cash and earns royalties on two approved partner drugs. J&J's January 2027 report and Protagonist's February 2027…TVTXTravere TherapeuticsMedium Travere Therapeutics' FILSPARI kidney-drug sales beat the third-quarter benchmark at $200.2 million, but new patient start forms slipped to 1,932 and Q4 carries an inventory drag. Fourth-quarter sales and the 1 December CEO handover decide…VIRVir BiotechnologyMedium Vir Biotechnology's hepatitis delta regimen met its pivotal ECLIPSE 1 endpoint on 8 November 2026 (44% response versus 0%), so the shares lean toward beating the S&P 500 over three months despite the new stock offering. The ECLIPSE 2 and 3…ZYMEZymeworksMedium Zymeworks shares have a modest edge over the S&P 500 after the company raised 2026 revenue guidance to $337–351 million on 9 November 2026; Roche antitrust clearance, expected in Q4 2026, and Jazz's next Ziihera sales report settle it.ABEOAbeona TherapeuticsLow Abeona Therapeutics' ZEVASKYN revenue grew 18% to $13.5 million in the third quarter but missed estimates, and a $3.75-a-share placement plus a stock-funded drug purchase left the shares at $2.30; they are more likely to lag the S&P 500.ABSIAbsciLow Absci Corporation's shares are more likely to lag the S&P 500 over three months because the price still assumes a hair-loss win for ABS-201; the 13-week interim data guided for December 2026 settle it.AMLXAmylyx PharmaceuticalsLow Amylyx Pharmaceuticals' shares are more likely to lag the S&P 500 because avexitide's Phase 3 win and $768.1 million of cash are already public, and the stock sits below the $35.50 August offering price. The 15 November 2026 full LUCIDITY…ANROAlto NeuroscienceLow Alto Neuroscience's depression program is funded through 2030 on company guidance, and the 10 November 2026 report left every timeline intact, but the shares have rallied hard with no efficacy data until 1H 2027 and are more likely to lag…ARCTArcturus Therapeutics HoldingsLow Arcturus Therapeutics has cash into 2028 but no dated FDA path for ARCT-810 and no dated Phase 3 decision for ARCT-032, so the shares are more likely to lag the S&P 500 until the company sets those dates.AVLNAvalyn PharmaLow Avalyn Pharma's shares are more likely to lag the S&P 500 over three months: the inhaled-antifibrotic case has no efficacy data until the MIST Phase 2b readout in the second half of 2027, and the 18 November 2026 conference update is the…AVTXAvalo TherapeuticsLow Avalo Therapeutics' abdakibart keeps a funded Phase 3 plan in hidradenitis suppurativa, but the shares sit near $7 after AbbVie's rival data; FDA feedback on the Phase 3 design, guided for H2 2026, settles the case.AVXLAnavex Life SciencesLow Anavex Life Sciences is more likely to lag the S&P 500: the shares hit a 52-week closing low of $1.06 on 11 November 2026 after three directors quit. The FDA's Rett pediatric meeting and the fiscal year-end report settle whether the slide…CABACabaletta BioLow Cabaletta Bio's rese-cel CAR-T program is more likely to lag the S&P 500 over three months: registrational myositis results slipped to the second half of 2027, and the shares closed at $1.33 on 12 November 2026, near their $1.28 closing…CGEMCullinan TherapeuticsLow Cullinan Therapeutics is more likely to lag the S&P 500 over three months: the shares closed at $10.19 on 12 November 2026, below both moving averages, even as the first-line zipalertinib filing was completed. The December CLN-978 data…CLDXCelldex TherapeuticsLow Celldex Therapeutics has two positive Phase 3 urticaria trials and cash guided through 2028, yet its shares closed at $30.15 on 11 November 2026, below both moving averages, and look more likely to lag the S&P 500. The late-2026 atopic…CPIXCumberland PharmaceuticalsLow Cumberland Pharmaceuticals shares are more likely to lag the S&P 500 while the ifetroban NDA for Duchenne heart disease has no date; $80.6 million of cash at 30 September 2026 settles funding, and a dated FDA submission would settle the…CRDLCardiol TherapeuticsLow Cardiol Therapeutics is more likely to lag the S&P 500 over three months: the MAVERIC Phase III topline is guided for mid-2027, and the company has begun selling stock under a US$75 million at-the-market program. That readout settles the…CRVSCorvus PharmaceuticalsLow Corvus Pharmaceuticals' soquelitinib shares are more likely to lag the S&P 500 over three months: the Angel eczema readout slipped to March 2027, so the main test sits past the window. $202.9 million of cash funds trials into the second…DFTXDefinium TherapeuticsLow Definium Therapeutics shares are likely to lag the S&P 500: its 9 November 2026 report kept the DT120 filing on track for the first half of 2027, yet the shares fell after it. The undated fourth-quarter FDA pre-filing meeting settles the…DNTHDianthus TherapeuticsLow Dianthus Therapeutics' shares are more likely to lag the S&P 500 than lead it over three months, because the case rests on one binary event: the Phase 2 MoMeNtum readout of claseprubart in multifocal motor neuropathy, guided to December…DSGNDesign TherapeuticsLow Design Therapeutics' shares are more likely to lag the S&P 500: a new $200 million stock-sale program adds supply while DT-216P2's regulatory path is unconfirmed; the company's Q4 2026 registrational-plans update settles it.DYNDyne TherapeuticsLow Dyne Therapeutics' shares are more likely to lag the S&P 500 over three months: the case rests on the FDA's 21 January 2027 decision on zeleciment rostudirsen in Duchenne and the Q1 2027 myotonic dystrophy topline, with cash funded into Q2…EDITEditas MedicineLow Editas Medicine's shares look more likely to lag the S&P 500 over three months: its 9 November 2026 report puts human efficacy data in the second half of 2027, so only first dosing and early safety data fall in the window.FDMT4D Molecular TherapeuticsLow 4D Molecular Therapeutics' gene therapy 4D-150 has no controlled efficacy data yet, so the shares are more likely to lag the S&P 500 until the randomized 4FRONT-1 wet AMD topline guided for the second quarter of 2027, while cash fell to…GHRSGH ResearchLow GH Research's shares are more likely to lag the S&P 500 over three months: they trade just above the $18.00 April 2026 offering price with no dated pivotal-trial start, and the third-quarter report, estimated for 20 November 2026, is the…GLUEMonte Rosa TherapeuticsLow Monte Rosa Therapeutics' Novartis milestones now fund its business, but the MRT-8102 heart-disease test, GFORCE-2, is guided only for H1 2027. Until it starts and reads out, shares trade on milestones, spending and start dates.HELPCybinLow Helus Pharma (formerly Cybin) is more likely to lag the S&P 500 over three months: the shares rest on one Phase 3 depression trial, APPROACH, guided to report in the fourth quarter of 2026, and a miss or a slip past 31 December 2026…IDYAIDEAYA BiosciencesLow IDEAYA Biosciences is more likely to lag the S&P 500: its Phase 3 OptimUM-010 trial closed on poor enrollment and brokers cut targets after the 3 November 2026 report. FDA acceptance of darovasertib and the IDE849 Phase 3 starts settle the…IKTInhibikase TherapeuticsLow Inhibikase Therapeutics' IKT-001 for pulmonary arterial hypertension is funded, with $193.3M cash on 30 September 2026, but dilution and warrant-dependent runway weigh on shares at $1.55; 2027 interim safety data is next.IVAInventivaLow Inventiva's shares are more likely to lag the S&P 500 over three months: funding is conditional and the lanifibranor MASH result is a coin flip on a single asset. The undated fourth-quarter 2026 NATiV3 topline settles the call.KYMRKymera TherapeuticsLow Kymera Therapeutics' shares are more likely to lag the S&P 500 because the price already reflects a clear win for oral eczema drug KT-621; the Phase 2b BROADEN2 topline, guided by year-end 2026, settles whether efficacy nears Dupixent's.MAZEMaze TherapeuticsLow Maze Therapeutics' kidney drug MZE829 has an early efficacy signal and cash guided into 2029, but the shares are more likely to lag the S&P 500: full HORIZON data slipped to early 2027 and the shares have already rallied.MGTXMeiraGTx HoldingsLow MeiraGTx's shares are more likely to lag the S&P 500 over three months: the US filing for its gene therapy bota-vec slipped to the first quarter of 2027, and the December 2026 European submission is the next test.NRIXNurix TherapeuticsLow Nurix Therapeutics is more likely to lag the S&P 500 over three months: Sanofi ended its STAT6 program on 3 November 2026 and the shares are down 42.3% in three months. The bexobrutideg poster at the ASH meeting on 13 December 2026 decides…NVAXNovavaxLow Novavax raised its 2026 adjusted revenue framework to $385–415 million on 5 November 2026, but the lift is mostly the known $125 million Sanofi milestone, and the shares closed at $9.98 on 11 November 2026, below pre-report levels.…NVCTNuvectis PharmaLow Nuvectis Pharma's shares are more likely to lag the S&P 500 over three months: NXP200 glioma data are out, and the remaining test is whether US IND filings for NXP100 and NXP200 land by the 31 December 2026 guide.PGENPrecigenLow Precigen's PAPZIMEOS is now profitable and cash-generating, but quarterly growth slowed to 37% and a rival RRP drug was approved, so the shares are more likely to lag the S&P 500 over three months; fourth-quarter revenue settles it.QUREuniQureLow uniQure's Huntington's gene therapy AMT-130 cleared the FDA filing stage with priority review and a 1 May 2027 decision date, yet the shares still closed at $22.71 on 10 November 2026; the advisory committee decides whether the weakened…RAPPRapport TherapeuticsLow Rapport Therapeutics' RAP-219 beat placebo in bipolar mania by 3.1 points, short of management's 4-point bar, but cash is guided through 2029; fourth-quarter 2026 seizure safety data decide whether tolerability concerns spread.RVMDRevolution MedicinesLow Revolution Medicines' shares are more likely to lag the S&P 500 over three months: they closed at $176.35 on 12 November 2026, and the fourth-quarter RASONQUE report, expected about February 2027, shows if the $197.6 million first quarter…RXRXRecursion PharmaceuticalsLow Recursion Pharmaceuticals' shares look more likely to lag the S&P 500 over three months: cash runs into 2029 and REC-4881 data held up, but every dated next step sits in 2027. An FDA agreement on the registrational trial settles the case.SNDXSyndax PharmaceuticalsLow Syndax Pharmaceuticals is more likely to lag the S&P 500 over three months: Revuforj sales are growing, yet the shares are down 51.9% in three months. The frontline leukemia data at ASH on 13 December 2026 and 14 December 2026 settle it.SRZNSurrozenLow Surrozen's cash now runs into 2029, but the shares at $31.88 already carry that news; with the resale registration for $11.60 placement stock due about 19 November 2026, they are more likely to lag the S&P 500 than lead it.STROSutro BiopharmaLow Sutro Biopharma's shares are more likely to lag the S&P 500 over three months: cash fell to $142.2 million at 30 September 2026, Merck ended MK-1484 on 7 November 2026, and the next STRO-004 data update is guided to the first half of 2027.STTKShattuck LabsLow Shattuck Labs' DR3-blocking antibody SL-325 has no patient efficacy data until the first half of 2028, and the shares closed at $4.99 on 9 November 2026 after the Q3 report; the Phase 2 trial starts decide the next step.SYRESpyre TherapeuticsLow Spyre Therapeutics' shares are more likely to lag the S&P 500 over three months: its three bowel-disease antibodies cleared single-agent trials, but combination data is not due until the third quarter of 2027 and the company keeps issuing…TSHATaysha Gene TherapiesLow Taysha Gene Therapies' Rett syndrome therapy TSHA-102 is more likely to lag the S&P 500 over three months; pivotal six-month interim data and FDA feedback on the filing route, guided to the first half of 2027, settle it.VERULow Veru's case rests on whether its oral drug enobosarm preserves lean mass alongside semaglutide; the PLATEAU 32-week interim, guided to calendar Q1 2027, settles it, while going-concern doubt and an open stock-sale program cap the shares.VSTMVerastemLow Verastem's shares look more likely to lag the S&P 500: its KRAS G12D drug VS-7375 is funded into the first half of 2028, but ovarian revenue missed forecasts and a $100M share program adds supply. The year-end 2026 Phase 3 start and…XENEXenon PharmaceuticalsLow Xenon Pharmaceuticals' shares are more likely to lag the S&P 500 because a December 2026 depression readout under a safety overhang now outweighs its pending epilepsy filing; FDA acceptance, due about 16 November 2026, and that readout…